32 completed, 23 active not recruiting, 11 recruiting, 9 terminated. 82 Phase 2, 15 Phase 1, 4 Phase 3.
Follow CTLA-4 Antigen: new trials by email Literature Review of CTLA-4 Antigen trials Research Report on CTLA-4 Antigen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 18 | 2026-04-21 | 2026-06-05 |
| Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Acral Melanoma, Advanced Cutaneous Melanoma | Phase 2 | Recruiting | Emory University | 99 | 2025-10-29 | 2025-11-12 |
| Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 55 | 2025-08-15 | 2026-07-31 |
| Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma Nivolumab, Ipilimumab, Surgical Procedure - Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | 26 | 2024-11-27 | 2026-08-05 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma | Phase 2 | Suspended | National Cancer Institute (NCI) | 50 | 2024-02-19 | 2026-10-19 |
| Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma Biopsy Procedure, Biospecimen Collection, Cabozantinib - Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma | Phase 2 | Active not recruiting | National Cancer Institute LAO | 66 | 2023-10-25 | 2026-10-09 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-10-28 |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial Avelumab, Axitinib, Biospecimen Collection - Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 240 | 2023-02-01 | 2026-10-23 |
| A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Ipilimumab, Nivolumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 15 | 2023-01-19 | 2026-08-04 |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study Cabozantinib, Ipilimumab, Nivolumab - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 54 | 2022-12-06 | 2026-08-19 |
| Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative Biopsy Procedure, Biospecimen Collection, Computed Tomography - Lung Adenocarcinoma, Lung Adenosquamous Carcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2022-10-07 | 2026-10-01 |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma Biospecimen Collection, Computed Tomography, Ipilimumab - Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 81 | 2022-06-02 | 2026-10-28 |
| Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer Computed Tomography, Ipilimumab, Magnetic Resonance Imaging - Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8 | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2022-02-08 | 2026-10-22 |
| Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer cfDNA blood test, Nivolumab, Ipilimumab - Non Small Cell Lung Cancer | Phase 2 | Terminated | University Health Network, Toronto | 5 | 2022-01-24 | 2026-01-08 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer Nivolumab, Ipilimumab, Carboplatin - Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Cancer | Phase 2 | Active not recruiting | Andrew J. Armstrong, MD | 41 | 2021-06-07 | 2026-04-06 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Ipilimumab, Nivolumab, Patient Observation - Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 150 | 2021-02-09 | 2026-09-15 |
| Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer Ipilimumab, Nivolumab - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Completed | Radboud University Medical Center | 69 | 2021-01-19 | 2026-01-06 |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases Binimetinib, Encorafenib, Ipilimumab - Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | SWOG Cancer Research Network | 112 | 2021-01-06 | 2026-09-15 |
Showing 20 of 82. Sign in to see all of them.
Melanoma (23) · Carcinoma, Renal Cell (6) · Prostatic Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Uveal Melanoma (5) · Brain Neoplasms (4) · Histiocytoma, Malignant Fibrous (4) · Sarcoma (4) · Clear-cell metastatic renal cell carcinoma (3) · Neoplasm Metastasis (3) · Bone Neoplasms (2) · Breast Neoplasms (2) · Carcinoma, Basal Cell (2) · Carcinoma, Endometrioid (2) · Carcinoma, Hepatocellular (2)
National Cancer Institute (NCI) (29) · M.D. Anderson Cancer Center (18) · Academic and Community Cancer Research United (2) · Mayo Clinic (2) · Northwestern University (2) · Shanghai Cell Therapy Research Institute (2) · University of Washington (2) · Alliance for Clinical Trials in Oncology (1) · Andrew J. Armstrong, MD (1) · Bristol-Myers Squibb (1) · CINJRegulatory (1) · Dana-Farber Cancer Institute (1) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Fred Hutchinson Cancer Center (1)
United States (77) · Canada (8) · China (2) · Puerto Rico (2) · Australia (1) · Guam (1) · Ireland (1) · Netherlands (1)
Frank S Hodi (3) · Huajun Jin, Ph.D (2) · Jiangtao Wang (2) · Qijun Qian, Ph.D (2) · Yan Sun (2) · Zhiwei Zhang, Ph.D (2) · A P Chen (1) · Adel Mandl (1) · Adi Diab (1) · Adil Daud, MD (1) · Adrian Sacher, M.D. (1) · Ahmad Tarhini (1) · Ahmed O Kaseb (1) · Alexander Shoushtari (1) · Amir A Jazaeri (1)
PMID 20082117, PMID 25369488, PMID 27269940, PMID 28223062, PMID 29246938, PMID 29370992, PMID 29983880, PMID 30249211, PMID 31401903, PMID 31969335, PMID 31998643, PMID 32192573, PMID 32691060, PMID 32850444, PMID 32853585, PMID 33125309, PMID 33362722, PMID 33603241, PMID 33636027, PMID 33882143, PMID 34032893, PMID 34380663, PMID 34413300, PMID 34503735, PMID 34716198, PMID 34780125, PMID 34980577, PMID 35031545, PMID 35065057, PMID 35537412, PMID 35613998, PMID 36648215, PMID 36928818, PMID 37328287, PMID 37505794, PMID 37592104, PMID 38243705, PMID 38358334, PMID 38391202, PMID 38737792, PMID 38934093, PMID 39067873, PMID 39133806, PMID 39343510, PMID 39343511, PMID 39384194, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40166913
U10CA180821 (9), U10CA180820 (8), P30CA015083 (4), U10CA180868 (4), U24CA196172 (4), U10CA021115 (3), U10CA180888 (3), UM1CA186704 (3), N01CM00032 (2), N01CM00038 (2), N01CM00071 (2), P30CA060553 (2), UM1CA186689 (2), UM1CA186691 (2), UM1CA186712 (2)